Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis, 2017 by P&S Market Research

GLOBAL INDUSTRY INSIGHT: Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

According to a new research report “Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments� published by P&S Market Research, Chronic obstructive pulmonary disease currently exhibits a pipeline with 65 drug candidates.

Explore

Report

at:

https://www.psmarketresearch.com/market-analysis/copd-therapeutics-

pipeline-analysis Chronic obstructive pulmonary disease pipeline in 2017 The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates, of which eight drug candidates are in Phase III stage of development, 24 drug candidates are in Phase II stage, nine drug candidates are in Phase I, 22 drug candidates are in Pre-Clinical stage and two drug candidates are in Discovery stage. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis. In this condition, lung cells lose their elasticity and get enlarged, which leads to reduction in the amount of gas exchange in the lungs. Sometimes, it progresses to form cancer, stroke and coronary artery disease.

Insights on pipeline segments As per the findings of the research, around 40.0% of the drug candidates of chronic obstructive pulmonary disease pipeline are being developed to be administered by inhalation route, 12.0% are being developed to be administered by oral route, 5.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by intravenous route, 3.0% are being developed to be administered by another route and 37.0% are being developed to be administered by other routes that are undisclosed.

Human

combinatorial

antibody

library

(HuCAL)

technology

platform

for

Chronic

Obstructive Pulmonary Disease drug development MorphoSys AG is using human combinatorial antibody library (HuCAL) technology platform for the development of CNTO6785 for the treatment of chronic obstructive pulmonary disease. The technology platform is used for the in vitro generation of highly specific and fully human antibodies.

HuCAL antibodies are produced in bacteria, and the technology enables in vitro selection to isolate antibodies with the desired characteristics. HuCAL is generated by de novo gene synthesis, and the

Š P&S Market Research. All rights reserved

2

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

large library is screened with a technique called phage display, to identify the antibody with a high affinity to the investigated antigen.

Explore

Report

Sample

at:

https://www.psmarketresearch.com/market-analysis/copd-

therapeutics-pipeline-analysis/report-sample Major companies collaborate for the development of Chronic Obstructive Pulmonary Disease Therapeutics Pipeline Many companies are involved in the development of drugs for the chronic obstructive pulmonary disease therapeutics pipeline, with their products in different phases. Chiesi Farmaceutici S.p.A., GlaxoSmithKline plc and AstraZeneca plc have their drug candidates in the Phase III stage of development. Adamis Pharmaceuticals Corporation has two drug candidates in Phase II stage of development. Novartis AG also has two drug candidates in Phase II stage of development.

Glenmark Pharmaceuticals Ltd. has two drug candidates in Pre-Clinical stage of development.

The research also found that various companies have collaborated for the development of chronic obstructive pulmonary disease therapeutics pipeline. In March 2017, Kyowa Hakko Kirin Co., Ltd. entered into an agreement with AstraZeneca plc for the exclusive rights of benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease in Asia. In June 2013, AstraZeneca plc acquired Pearl Therapeutics, Inc., which was involved in the development of inhaled small-molecule therapeutics for respiratory disease.

Some of the key players developing drugs for the treatment of chronic obstructive pulmonary disease include AstraZeneca plc, GlaxoSmithKline plc, Adamis Pharmaceuticals Corporation, Chiesi Farmaceutici S.p.A., Cytokinetics, Inc., Novartis AG and Theravance Biopharma R & D, Inc. Pre-Purchase Enquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=copdtherapeutics-pipeline-analysis Chapter 1. Research Background 1.1 Research Objectives 1.2 Definition 1.3 Research Scope 1.3.1 Pipeline analysis by phase 1.3.2 Pipeline analysis by route of administration

Š P&S Market Research. All rights reserved

3

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

1.3.3 Pipeline analysis by molecule type 1.4 Key Stakeholders Chapter 2. Research Methodology 2.1 Secondary Research 2.2 Primary Research 2.2.1 Breakdown of primary research respondents 2.2.1.1 By industry participant 2.2.1.2 By company type Chapter 3. Executive Summary Chapter 4. Pipeline Outlook 4.1 Overview 4.2 Key Drivers 4.2.1 Combination therapies for COPD pipeline 4.2.2 Use of various promising targets 4.3 Key Barriers 4.3.1 No specific symptoms 4.3.2 Scarcity of tools in COPD diagnosis 4.4 Chronic Obstructive Pulmonary Disease Pipeline Analysis 4.4.1 Pipeline analysis by phase 4.4.2 Pipeline analysis by molecule type 4.4.3 Pipeline analysis by route of administration 4.4.4 Pipeline analysis by company Chapter 5. Chronic Obstructive Pulmonary Disease Pipeline Analysis by Phase (2017) 5.1 Phase III 5.1.1 (Beclometasone dipropionate + Formoterol fumarate + Glycopyrronium bromide) 5.1.1.1 Clinical trials

Š P&S Market Research. All rights reserved

4

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

5.1.1.2 Strategic developments 5.1.1.3 Technology 5.1.2 Benralizumab 5.1.2.1 Clinical trials 5.1.2.2 Strategic developments 5.1.3 (Budesonide + Glycopyrronium + Formoterol Fumarate) 5.1.3.1 Clinical trials 5.1.3.2 Strategic developments 5.1.3.3 Technology 5.1.4 Glycopyrronium 5.1.4.1 Clinical trials 5.1.4.2 Strategic developments 5.1.4.3 Technology 5.1.5 (Glycopyrronium + Formoterol Fumarate) 5.1.5.1 Clinical trials 5.1.5.2 Strategic developments 5.1.5.3 Financing 5.1.5.4 Technology 5.1.6 HCP-1202 5.1.6.1 Clinical trials 5.1.7 Mepolizumab 5.1.7.1 Clinical trials 5.1.8 Revefenacin 5.1.8.1 Clinical trials 5.1.8.2 Clinical results 5.1.8.3 Strategic developments

Š P&S Market Research. All rights reserved

5

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

5.2 Phase II 5.2.1 Abediterol 5.2.1.1 Clinical trials 5.2.1.2 Strategic development 5.2.2 Acumapimod 5.2.2.1 Clinical trials 5.2.2.2 Strategic development 5.2.3 APC-1000 5.2.3.1 Technology 5.2.4 AZD7594 5.2.4.1 Clinical trials 5.2.5 AZD8871 5.2.5.1 Clinical trials 5.2.6 Batefenterol 5.2.6.1 Clinical trials 5.2.7 CHF6001 5.2.7.1 Pre- Clinical study 5.2.7.2 Clinical trials 5.2.7.3 Clinical results 5.2.7.4 Technology 5.2.8 CK-2127107 5.2.8.1 Clinical trials 5.2.8.2 Strategic development 5.2.9 CNTO6785 5.2.9.1 Clinical trials 5.2.9.2 Technology

Š P&S Market Research. All rights reserved

6

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

5.2.10 Danirixin 5.2.10.1 Clinical trials 5.2.11 Emeramide 5.2.11.1 Clinical trials 5.2.12 Fluticasone 5.2.12.1 Technology 5.2.13 Glycopyrronium bromide 5.2.13.1 Clinical results 5.2.13.2 Strategic development 5.2.13.3 Technology 5.2.14 Heparin 5.2.14.1 Clinical study 5.2.14.2 Patent 5.2.15 Glycopyrrolate Bromide 5.2.15.1 Clinical trials 5.2.15.2 Technology 5.2.16 Ivacaftor 5.2.16.1 Clinical trials 5.2.17 Lebrikizumab 5.2.17.1 Clinical trials 5.2.18 Nemiralisib 5.2.18.1 Clinical trials 5.2.19 PUR0200 5.2.19.1 Clinical trials 5.2.19.2 Strategic development 5.2.19.3 Technology

Š P&S Market Research. All rights reserved

7

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

5.2.20 QBW251 5.2.20.1 Clinical trials 5.2.21 RPL554 5.2.21.1 Pre- Clinical study 5.2.21.2 Clinical trials 5.2.21.3 Clinical results 5.2.21.4 Strategic development 5.2.22 SB010 5.2.23 Tiotropium bromide 5.2.23.1 Clinical trials 5.2.23.2 Strategic development 5.2.24 YPL-001 5.2.24.1 Clinical trials 5.3 Phase I 5.3.1 APL1 5.3.2 AZD7986 5.3.3 Bedoradrine 5.3.3.1 Clinical trials 5.3.4 BI443651 5.3.4.1 Clinical trials 5.3.5 CHF6297 5.3.5.1 Clinical trials 5.3.6 FP-025 5.3.6.1 Clinical trials 5.3.6.2 Strategic developments 5.3.7 MEDI3506

Š P&S Market Research. All rights reserved

8

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

5.3.7.1 Clinical trials 5.3.8 Triple combination 5.3.8.1 Technology 5.3.9 TRN-157 5.3.9.1 Clinical trials 5.4 Pre-Clinical 5.5 Discovery Chapter 6. Competitive Landscape 6.1 Key Players Benchmarking for Chronic Obstructive Pulmonary Disease Drug Candidates 6.2 SWOT Analysis of Chronic Obstructive Pulmonary Disease Pipeline Chapter 7. Company Profiles 7.1 GlaxoSmithKline plc 7.1.1 Business overview 7.1.2 Product and service offerings 7.2 AstraZeneca plc 7.2.1 Business overview 7.2.2 Product and service offerings 7.3 Novartis AG 7.3.1 Business overview 7.3.2 Product and service offerings 7.4 F. Hoffmann-La Roche AG 7.4.1 Business overview 7.4.2 Product and service offerings 7.5 MorphoSys AG 7.5.1 Business overview 7.5.2 Product and service offerings

Š P&S Market Research. All rights reserved

9

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

7.6 Boehringer Ingelheim GmbH 7.6.1 Business overview 7.6.2 Product and service offerings 7.7 Adamis Pharmaceuticals Corporation 7.7.1 Business overview 7.7.2 Product and service offerings 7.8 Theravance Biopharma, Inc. 7.8.1 Business overview 7.8.2 Product and service offerings 7.9 Mereo BioPharma Group plc 7.9.1 Business overview 7.9.2 Product and service offerings 7.1 Cytokinetics, Inc. 7.10.1 Business overview 7.10.2 Product and service offerings Chapter 8. Appendix 8.1 Abbreviations

Browse

Other

Related

Report

at:

https://www.psmarketresearch.com/industry-

report/pharmaceuticals

About P&S Market Research P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

Š P&S Market Research. All rights reserved

10

Chronic

Obstructive

Pulmonary

Disease

Exhibits

Emerging

Pipeline with 60+ Drug Candidates

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact: Kundan Manager – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 Toll-Free: +1-888-778-7886 (USA/Canada) Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com

© P&S Market Research. All rights reserved

11